Moderna and Merck's Cancer Vaccine Shows Positive Results in Phase 3 Melanoma Trial
Moderna and Merck's experimental personalized cancer vaccine, Intismeran, combined with Merck's immunotherapy Keytruda, showed promising interim results in a large Phase 3 trial for high-risk melanoma. The treatment met primary and secondary goals by significantly improving recurrence-free survival and reducing cancer spread compared to Keytruda alone. The study continues to evaluate overall survival and other outcomes. No new safety concerns were reported, and detailed data will be shared with regulators and at upcoming medical meetings.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (76/100). Lens Score 40/100.
Outlets measured: economictimes, moneycontrol, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 19 Aug, 01:04 pm. Other outlets followed.